Sentences with phrase «new mechanism of action»

Explore further: New mechanism of action for DISC1, a psychiatric disorder agent, revealed by scientists

«Our study has found that Hsp90 inhibition can specifically stop resistance to hormone treatments in prostate cancer, through a completely new mechanism of action involving the processing of messenger RNA.

This is the result of one of the largest multicentre, international studies so far into difficult - to - treat rheumatoid arthritis, focussing on this new mechanism of action, an interleukin - 6 cytokine blockade.

Prof. Christoph Dehio's research group at the Biozentrum, University of Basel, has uncovered a new mechanism of action of toxins from the group of FIC proteins.

«The study demonstrates a new mechanism of action for INF - β therapies,» says Dr. Rostami.

High profits may be justified if novel products offer significant benefits to patients (thus producing indirect economic value through the patients» restored health) or if they represent significant pharmacologic advances over their predecessors — offering new mechanisms of actions and emblematic of high - risk research.

Professor Sadler comments that this research could lead to new cancer treatments: «Cancer drugs with new mechanisms of actions which can combat resistance and have fewer side - effects are urgently needed.

The sole drug target for existing treatments was found serendipitously, and no medications with fundamentally new mechanisms of action have been developed since the 1950s.

Not exact matches

You'll want to create tasks for regular communication (weekly check - in emails with «helpers»), ongoing lists for all SEO opportunities, dates for timely opportunities, rating mechanisms for prioritization and a list of actions items for each new opportunity.

The next objective of the researchers is to decode the action mechanism of TREX2 in the development and maintenance of psoriasis, so as to design new therapeutic strategies for the treatment of this disease.

Determining the detailed molecular mechanism that mediates the therapeutic actions of cannabidiol may suggest development strategies for new drugs aimed at GPR55, according to the researchers.

«This is a very slow, labor intensive process that typically requires many months of effort, and frequently ends with discovering that the molecule does not have a new or interesting mechanism of action,» he added.

But a serendipitous discovery may someday give doctors a new countermeasure against the disease: Researchers report in tomorrow's Science that they have identified a possible mechanism of action for «lethal factor» (LF), a toxic protein produced by the anthrax bacillus that is thought to be one of the principal causes of death in infected individuals.

Furthermore, the results broaden the spectrum of antiviral activity of these compounds and shed new light on their mechanisms of action, said Dr. Kainov.

The drug's mechanism of action was entirely new: Instead of attacking cancer cells (like chemo), or indiscriminately revving up the immune system (like IL - 2), ipilimumab blocked a single receptor on one type of immune cell.

«There is an urgent clinical need for new treatments for depression with novel mechanisms of action.

The report's «Top 10» list of recommended actions includes a new international treaty with strong monitoring and enforcement mechanisms; domestic and local regulatory actions, such as bans of the most common and damaging types of plastic litter; extended producer - responsibility programs; and the creation of an «ocean friendly» certification program for plastic products.

The brief describes the inadequacy of existing international legal mechanisms to resolve this litter crisis, calling on the global community to develop a new international treaty while also urging immediate action to implement regional and local solutions.

Analyses of the differences in the mechanisms of action of both drugs may provide a blueprint for the development of new adjuvant treatments for LNB.

«Indeed, as we look ahead to cataloguing them comprehensively across all cancers and to deeply understanding their mechanisms of action, we will need to propel these new methodologies even further.»

«Our research highlights a potentially new mechanism of dinaciclib action, and raises the possibility that this agent could be a useful addition to current multiple myeloma and myeloid leukemia therapies.»

In the current issue of «Cell Reports,» the scientists describe the mechanism of action and also explain why their discovery provides new insights into the evolution of pathogens.

According to the authors of the study, in future researches it will be necessary to know about the action mechanism of the new products - highly selective and with low cell toxicity on in vitro tests - and broaden preclinical studies with laboratory animal models.

Ishmael said even if coibamide A itself can not enter the brain or turns out to have adverse side effects, knowing its structure and mechanism of action can help researchers develop new drugs that mimic coibamide A's effects.

At Merck Frosst Canada, I have been an integral part of the discovery of a new molecule, the testing of its mechanism of action, the validation of its safety and efficacy in Phase IIb and III clinical trials, the market approval of the resulting product, and the subsequent management of patients and their disease.

A potential new antidepressant and anti-anxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.

The researchers showed that Hsp90 inhibition reduced production of AR - V7 through a new and unexpected mechanism of action — by changing the way that messenger RNA molecules carrying the code for AR - V7 are processed.

The authors also discovered that statin stimulated the degradation of FGFR3 in mice by targeting the proteasomal pathway, offering new insight on the mechanism of action.

The collaborative work by Merck and Emulate researchers enabled new functionality for the Small Airway Lung - Chip to demonstrate the mechanism of action for therapeutic compounds acting on inflammatory disease states in the small airway, particularly in diseases such as asthma.

The study was led by Dale Boger, co-chair of TSRI's department of chemistry, who said the discovery made the new version of vancomycin the first antibiotic to have three independent «mechanisms of action'to kill bacteria.

The major players in the arthritis drug market include Remicade ® (infliximab), Humira ® (adalimumab), Enbrel ® (etanercept), Cimzia ® (certolizumab pegol) and Simponi ® (golimumab), while biosimilars of the above as well as new drugs with novel mechanisms of action are under development.

The system can be used by researchers as a model to elucidate how viral infections contribute to exacerbations, gain insight into mechanism of action of drugs, and could potentially help identify new therapeutic targets.

Our team is using a combination of cutting - edge proteomics, molecular and cellular biology strategies to uncover new alt - EJ players and decipher their mechanisms of action in cancer.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trmechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trMechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) trmechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

«We should look also at older drugs that may have been discarded, and perhaps work more to understand the mechanism of action of acetaminophen to develop a new, more effective and less toxic drug of the same class, or develop new classes of painkillers,» Moore suggested.

The gearbox's shift mechanism has been thoroughly overhauled with the new mechanism designed to provide a tighter, more precise and cleaner shift action — a bugbear of the standard Exige.

Changed the method for rendering the world from Item Frames (1.8.x) to diamond hoe damage values (1.9.x) Added collision detection Added walking animations New control mechanism - select hotbar slot, then right click to run action (allows single pushes and button holding) Converted the Pokédex and other static menu items from maps to textures Results: Significantly reduced file size, elimination of ~ 25,000 command blocks (mostly from the Pokédex), more responsive controls

In the post-war America of the 1940s and 1950s, a number of New York Abstract Expressionist Artists captured the imagination of the public with regard to the mechanisms of their craft − a style described as «Action Painting.»

What ends up enshrined in the FVA will be determined by the concurrent discussion on a New Market Mechanism (NMM) for mitigation action and the decision on the role of Non Market Approaches (NMA).

ACR remains steadfast in our commitment to demonstrate the value of market - based mechanisms to mitigate the impacts of climate change, and we are eager to collaborate more closely with organizations and institutions in the U.S. and around the world to pioneer new approaches to incentivize climate action.

Durban calls for defining ``... a new market - based mechanism... to enhance the cost - effectiveness of, and to promote, mitigation actions....»

Diego Enriques, City of Quito, reminded of the importance to include the private and finance sector to create new, simple, innovative financing mechanisms for local actions.

The new AWG - LCA 8, item 3 on nationally - appropriate mitigation actions (NAMAs) by developing country parties released this morning creates either a registry as part of the financial mechanism or some other mechanism to record NAMAs from developing countries, specifying only NAMAs seeking or receiving support would be required for verification through an international mechanism or registry.

We emphasized the Global Action Framework for Localizing Climate Finance as a key mechanism to mobilize actors and catalyze new financial standards, channels and coordination to the benefit of local and subnational governments.

Energy Guardian (2/14/13) reports: «Senate Environment and Public Works Chairman Barbara Boxer on Thursday put a new carbon emissions fee bill on track for committee action by this summer, even as the chances for the proposal to be enacted appeared slim... The fee is part of a package of two climate bills by Boxer, D - Calif., and Sen. Bernie Sanders, I - Vt., that sidesteps President Barack Obama's call for a market - based mechanism to cut greenhouse gas emissions.»

Some of the pre-publicity to CA 2006 suggested that the statutory duties combined with the statutory derivative action (CA 2006, s 260) rang in a new era in shareholder / director relationships, providing mechanisms for greater shareholder control and action.

Expressly conceptualizing reputation within its proper context (i.e., recognizing its contingent and constructed nature and taking account of the new mechanisms available to individuals to affect that construction) should lead to an adaptation of defamation law into two related but distinct causes of action: one for individuals who lack the resources and wherewithal to actively construct their reputation and one for public figure individuals who do possess those advantages.

Orchestrated the 2010 HUD Employee Viewpoint Survey (EVS) Action Plan from end - to - end and initiated the plan for 2012; collaborated with the Office of the Secretary, Public Affairs, Strategic Planning and HUD program offices; developed score cards as a mechanism for tracking quarterly progress and identifying barriers; assessed new initiatives to ensure the specified goals in the Action Plan are aligned with the Secretary's vision and HUD's overall mission.